Remove 2018 Remove Chemotherapy Remove Patient Care
article thumbnail

The changing treatment landscape of acute lymphoblastic leukaemia

Hospital Pharmacy Europe

The CAR T-cell therapy tisagenlecleucel has recently been given the green light for routine rollout on the NHS to treat paediatric patients with acute lymphoblastic leukaemia. These patients often reach the ceiling for toxicity in terms of chemotherapy and radiotherapy in the context of a bone marrow transplant.

article thumbnail

Solutions for Constipation Relief

The Thyroid Pharmacist

One 2018 study found that among 80 people with IBS, 19 percent had undiagnosed thyroid dysfunction. [11] Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. Published 2016 Jun 27.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency. These are all important and necessary topics that help cancer centers run effectively and deliver exceptional patient care. Desimone R.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release. August 24, 2018. 2 REFERENCES 1. Schwenk E, Mariano E, et al. Doi:10.4097/kja.d.18.00217

FDA 73
article thumbnail

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

Beyond significant cost savings, biosimilar uptake has been shown to simultaneously improve patient access, varying by country. A subsequent change in guidance moved this biologic to a first-line treatment, resulting in an increase in the number of patients who could receive this much-needed treatment by 104%. Published 8 March 2019.